ATE483459T1 - Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin - Google Patents

Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Info

Publication number
ATE483459T1
ATE483459T1 AT00941235T AT00941235T ATE483459T1 AT E483459 T1 ATE483459 T1 AT E483459T1 AT 00941235 T AT00941235 T AT 00941235T AT 00941235 T AT00941235 T AT 00941235T AT E483459 T1 ATE483459 T1 AT E483459T1
Authority
AT
Austria
Prior art keywords
oxybutynin
smooth muscle
desethyloxybutynin
treating
optically pure
Prior art date
Application number
AT00941235T
Other languages
English (en)
Inventor
A Aberg
Original Assignee
Watson Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Watson Pharmaceuticals Inc filed Critical Watson Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE483459T1 publication Critical patent/ATE483459T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00941235T 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin ATE483459T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/015515 WO2001093683A1 (en) 2000-06-07 2000-06-07 Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin

Publications (1)

Publication Number Publication Date
ATE483459T1 true ATE483459T1 (de) 2010-10-15

Family

ID=21741461

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941235T ATE483459T1 (de) 2000-06-07 2000-06-07 Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin

Country Status (9)

Country Link
EP (1) EP1286591B1 (de)
JP (1) JP5684964B2 (de)
CN (3) CN1454054A (de)
AT (1) ATE483459T1 (de)
AU (2) AU5596600A (de)
CA (1) CA2378754A1 (de)
DE (1) DE60045082D1 (de)
ES (1) ES2350330T3 (de)
WO (1) WO2001093683A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1455776A4 (de) * 2001-12-21 2006-05-17 Bridge Pharma Inc Nicht-arrhythmogener metabolit von oxybutynin
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
DK1629850T4 (da) * 2004-08-24 2013-07-01 Nutricia Nv Næringssammensætning indeholdende ufordøjelige oligosaccharider
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
KR20190060879A (ko) 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
GB2507884B (en) 2011-06-03 2019-10-23 Signpath Pharma Inc Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10258691B2 (en) 2014-06-03 2019-04-16 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
US20140135392A1 (en) * 2012-11-13 2014-05-15 NeuRx Pharmaceuticals LLC Methods for the treatment of sialorrhea
CN103169660B (zh) * 2013-04-15 2015-04-08 石正国 一种制备高包封率的利巴韦林脂质体口服乳
EP3082768B1 (de) * 2013-12-18 2023-02-22 Signpath Pharma Inc. Liposomale abschwächung von arzneimittelinduzierter hemmung des kardialen ikr-kanals
EP3448374B1 (de) 2016-04-27 2025-02-12 Signpath Pharma Inc. Prophylaxe von arzneimittelbedingtem atrioventrikulärem block
EP4146621A1 (de) * 2020-05-05 2023-03-15 Apnimed, Inc. (Delaware) Polymorphe formen von (r)-oxybutyninhydrochlorid
UY39313A (es) * 2020-07-03 2022-01-31 Phoxgen Ltd Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
CN117396460A (zh) * 2021-05-04 2024-01-12 爱普宁公司(特拉华) (r)-奥昔布宁d-苹果酸盐的固体形式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008269A (en) * 1970-05-05 1977-02-15 William H. Rorer, Inc. Phenylacetic acids
IT1231237B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati eterociclici
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters

Also Published As

Publication number Publication date
CN1454054A (zh) 2003-11-05
CN1451388A (zh) 2003-10-29
DE60045082D1 (de) 2010-11-18
JP5684964B2 (ja) 2015-03-18
AU2000255966B2 (en) 2005-03-24
JP2003535110A (ja) 2003-11-25
EP1286591A1 (de) 2003-03-05
EP1286591B1 (de) 2010-10-06
WO2001093683A1 (en) 2001-12-13
AU2000255966A1 (en) 2002-03-07
AU5596600A (en) 2001-12-17
CA2378754A1 (en) 2001-12-13
ES2350330T3 (es) 2011-01-21
EP1286591A4 (de) 2007-04-04
CN101108176A (zh) 2008-01-23

Similar Documents

Publication Publication Date Title
ATE483459T1 (de) Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin
CY1119029T1 (el) Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
EP1463531A4 (de) Verfahren zur hemmung okularer vorgänge
CA2451474A1 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
AU2001249091A1 (en) Novel methods using cholinesterase inhibitors
MXPA03000809A (es) Polimero de polisiloxano, procedimiento para su preparacion y su uso.
DE60027769D1 (de) Pyrrolidin-derivate als inhibitoren von cyclischer amp-phosphodiesterase
NO20043038L (no) Polymorfe former av klopidogrel-hydrogensulfat
EP1862457A3 (de) Fluoropyrrolidine als Dipeptidylpeptidasehemmer
EA200700116A1 (ru) Четвертичные соли, антагонисты ccr2
GEP20084325B (en) Purine compounds and uses thereof as cannabinoid receptor ligandspurine compounds and uses thereof as cannabinoid receptor ligands
IS7983A (is) Notkun á palonsetron til að meðhöndla ógleði og uppköst eftir aðgerðir
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
ATE197762T1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
CY1106409T1 (el) Παραγωγα κινολινης
WO2006050045A3 (en) Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2001087849A3 (en) Modulators of tnf- alpha signaling
DK1220852T3 (da) Substituerede diazepaner
WO2003084928A8 (en) Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers
WO2003092611A3 (en) Methods of inducing formation of functional and organized lymphatic vessels
FR2872508B1 (fr) Composition de traitement d'un verre pour en ameliorer la resistance mecanique par guerison des defauts de surface, procedes de traitement correspondants et verres traites obtenus
ATE278722T1 (de) Organische polymere
NO20042138L (no) Forbindelser og fremgangsmate for behandling av hyperaktiv blaere
EP1152760A4 (de) Verwendung von 4-aminopyridin zur behandlung von peripheralen neuropathien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties